Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Top Cited Papers
Open Access
- 29 March 2017
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 76 (6), 1102-1107
- https://doi.org/10.1136/annrheumdis-2016-210711
Abstract
Objectives To perform a systematic literature review (SLR) informing the 2016 update of the recommendations for the management of rheumatoid arthritis (RA). Methods An SLR for the period between 2013 and 2016 was undertaken to assess the efficacy of glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and targeted synthetic DMARDs (tsDMARDs) (tofacitinib and baricitinib) in randomised clinical trials. Results For GCs, four studies were included in the SLR. Patients without poor prognostic factors experienced benefit when GCs were added to methotrexate (MTX). Lower doses of GCs were similar to higher doses. For csDMARDs, two new studies comparing MTX monotherapy with combination csDMARD were included in the SLR. In the tREACH trial at the end of 12 months no difference between the groups in disease activity, functional ability and radiographic progression was seen, using principles of tight control (treat-to-target). In the CareRA trial, combination therapy with csDMARDs was not superior to MTX monotherapy and monotherapy was better tolerated. For tsDMARDs, tofacitinib and baricitinib were shown to be more effective than placebo (MTX) in different patient populations. Conclusions Addition of GCs to csDMARD therapy may be beneficial but the benefits should be balanced against the risk of toxicity. Under tight control conditions MTX monotherapy is not less effective than combination csDMARDs, but better tolerated. Tofacitinib and baricitinib are efficacious in patients with RA, including those with refractory disease.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trialAnnals Of The Rheumatic Diseases, 2014
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid ArthritisAnnals of Internal Medicine, 2013
- A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeksAnnals Of The Rheumatic Diseases, 2013
- Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimenRheumatology, 2013
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trialAnnals Of The Rheumatic Diseases, 2012
- Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)Annals Of The Rheumatic Diseases, 2012
- Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literatureAnnals Of The Rheumatic Diseases, 2008
- EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals Of The Rheumatic Diseases, 2007